| Mar'20 | Dec'19 | Sep'19 | Jun'19 | Mar'19 | Dec'18 | Sep'18 | Mar'18 |
|---|---|---|---|---|---|---|---|
Research and development ("R&D") expenses, net | |||||||
0 | - | - | - | 0 | - | - | - |
General and administrative expenses | |||||||
0 | - | - | - | 0 | - | - | - |
Operating costs | |||||||
- | - | 1,022 | 404 | 0 | 0 | 0 | 0 |
Operating Loss | |||||||
-24,449 | -22,207 | -1,022 | -404 | 0 | 0 | 0 | 0 |
Finance income, net | |||||||
0 | - | - | - | 0 | - | - | - |
Interest income on marketable securities held in Trust Account | |||||||
- | - | 0 | - | - | - | - | - |
Interest income - other | |||||||
- | - | 0 | - | - | 0 | - | - |
Unrealized loss on marketable securities held in Trust Account | |||||||
- | - | - | - | - | 0 | - | - |
Other income | |||||||
- | - | 0 | - | - | 0 | - | - |
Loss before income tax | |||||||
- | -20,563 | 238 | 482 | 0 | 0 | 0 | 0 |
Income tax | |||||||
- | - | 0 | - | - | 0 | - | - |
Net Loss | |||||||
-23,239 | -20,563 | 55 | 347 | 0 | 0 | 0 | 0 |
Basic and diluted loss per Ordinary Shares | |||||||
0.26 | 4.06 | -0.25 | -2.35 | 2.20 | 0.00 | 0.00 | 0.00 |
Weighted average number of Ordinary Shares outstanding, basic and diluted | |||||||
22,897 | 15,804 | 2,239 | 2,414 | 2,005 | 1,815 | 1,750 | 1,750 |